Revolution Medicines prices RASONQUE at $39,800 per month

The U.S. Food and Drug Administration approved Revolution Medicines' (NASDAQ: RVMD) RASONQUE™ (daraxonrasib) on August 26, 2026, for adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

The approval was based on data from RASolute 302, a global, randomized Phase 3 clinical trial comparing RASONQUE against investigator's choice of cytotoxic chemotherapy in patients with previously treated metastatic pancreatic adenocarcinoma.

RASONQUE is administered as a once-daily oral tablet. The wholesale acquisition cost is $39,800 for a 30-day supply at the recommended daily dose. The drug is now available in the United States for physicians to prescribe to eligible patients.

You May Also Be Interested In

• CDW to acquire data and AI firm Lovelytics for $525 million
• Prologis (PLD) Declares $1.07 Quarterly Dividend; 3.1% Yield
• Solowin Holdings unit signs non-binding MOU with EvolveQ on AI and quantum